Cemiplimab
Cemiplimab is a monoclonal antibody used in the treatment of certain types of cancer. It is marketed under the brand name Libtayo. Cemiplimab is specifically designed to target the programmed cell death protein 1 (PD-1) receptor, a protein found on the surface of T cells, which are a type of white blood cell involved in the immune response.
Mechanism of Action[edit]
Cemiplimab works by inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This interaction normally acts as a "brake" on the immune system, preventing T cells from attacking the body's own tissues. However, many tumors exploit this pathway to evade immune detection. By blocking PD-1, cemiplimab releases this brake, allowing T cells to recognize and destroy cancer cells more effectively.
Clinical Use[edit]
Cemiplimab is approved for the treatment of cutaneous squamous cell carcinoma (CSCC), a common form of skin cancer. It is indicated for patients with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or radiation. The drug is administered via intravenous infusion, typically every three weeks.
Development and Approval[edit]
Cemiplimab was developed by Regeneron Pharmaceuticals and Sanofi. It received FDA approval in 2018 for the treatment of advanced CSCC. The approval was based on clinical trials demonstrating significant tumor shrinkage in a substantial proportion of patients.
Side Effects[edit]
Common side effects of cemiplimab include fatigue, rash, and diarrhea. More serious immune-mediated side effects can occur, such as pneumonitis, hepatitis, and endocrinopathies. Patients receiving cemiplimab require monitoring for these adverse effects, and treatment may need to be adjusted or discontinued if severe reactions occur.
Research and Future Directions[edit]
Ongoing research is exploring the use of cemiplimab in other types of cancer, including non-small cell lung cancer (NSCLC) and basal cell carcinoma (BCC). Combination therapies with other immunotherapies or chemotherapy agents are also under investigation to enhance its efficacy.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
